Bone Biologics (OTC:BBLG) Stock Price Down 4.5% – Should You Sell?

Bone Biologics Co. (OTC:BBLG)’s share price was down 4.5% during mid-day trading on Wednesday . The stock traded as low as $1.25 and last traded at $1.26. Approximately 21,851 shares traded hands during trading, a decline of 99% from the average daily volume of 1,505,719 shares. The stock had previously closed at $1.32.

Bone Biologics Stock Performance

The business’s fifty day simple moving average is $1.65 and its 200 day simple moving average is $1.57. The stock has a market cap of $3.08 million, a price-to-earnings ratio of -0.02 and a beta of 0.45.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.